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STUDY ON INCIDENCE OF CONTRAST 
INDUCED NEPHROPATHY IN PATIENTS                     
UNDERGOING CONTRAST USING PROCEDURE-CORONARY 
ANGIOGRAM WITH NORMAL RENAL FUNCTION 
 
Abstract 
           Iodinated contrast media used for radiological diagnostic and 
therapeutic procedures are associated with the incidence of contrast 
induced nephropathy, which is the third leading cause of acute kidney 
injury next to ischeamic renal injury and nehrotoxic medications.It 
also increases the in hospital mortality of the patients.The incidence is 
particularly more in patients  subgroup who are undergoing cardiac 
related procedures. 
         The incidence of CIN is associated with multiple risk factors 
,and we have studied some of such risk factors namely,age and gender 
of the patients, hypertension and diabetic status of the patient,smoking 
history, intake of nephrotoxic drugs like ACE inhibitors, NSAIDS, 
Nephrotoxic antibiotics, Diuretics and the hydration and anemic status 
of the patients, who are undergoing coronary angiogram, a contrast 
using procedure having normal renal function, over a period of three 
months, in our hospital.Out of the risk factors studied, the most 
contributing risk factor is diabetic status of the patient , according to 
our study.The inclusion of only small number of patients, the 
inclusion of only some of the risk factors involved ,and absence of use 
of any prophylactic measures either pharmacological or non 
pharmacological for the prevention of contrast induced nephropathy 
are some of the limitations in our study.Also there is need for long 
term followup of the patient to study for the incidence of chronic 
kidney disease. 
Key words: Contrast induced nephropathy, Risk factors, Coronary 
angiogram, Iodinated contrast media 
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INTRODUCTION 
               
          Intravascular contrast media which are iodinated are being used 
for diagnostic and therapeutic procedures done radiologically.This has 
led to the rise in the occurrence of procedure related contrast induced 
nephropathy (CIN)⁽¹⁻³⁾.The incidence of deterioration in the renal 
function associated with radiologic procedures is usually less in the 
general population, but its incidence may be increased in some patient 
subgroups, particularly in patients undergoing cardiac related studies. 
Experiences from multiple centres varies widely⁽⁴⁻⁸⁾.  
                Multiple risk factors have been reported, concerned with the 
development of CIN⁽¹⁻⁸⁾.However, occurrence of two or more factors 
together is rather common in day to day practice, and their additive 
effect on renal function is not well studied. This urges the necessity for 
wide assessment of the effect of these variable risk factors on the 
development of CIN. 
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            CIN is the third leading cause of hospital acquired acute kidney 
injury (next to decreased renal perfusion and nephrotoxic 
medications)⁽⁹⁾.In hospital mortality rate of CIN is as high as 14%⁽¹¹⁾.In 
patients with multiple risk factors, incidence of CIN can rise upto 50% 
or even greater⁽¹²⁾. 
             CIN increases the length of  stay in the hospital, need for extra 
medical care, and also the mortality⁽¹³⁾.This study aims to study the 
incidence of contrast induced nephropathy in contrast using procedure 
– coronary angiogram, in patients who have no abnormal renal 
function. 
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AIM OF THE STUDY 
                     
                  To study the incidence of contrast induced nephropathy in 
patients undergoing contrast using procedure- coronary angiogram,  
with normal renal function .  
14 
Review of Literature  
                 Contrast induced nephropathy is defined as a new onset or an 
exacerbation of existing renal dysfunction after contrast administration 
in the absence of other causes, with s.creatinine increase of ≥25% over 
the baseline value or an absolute increase of  ≥0.5mg/dl⁽¹⁴⁻¹⁸⁾. 
S.creatinine starts rising within 24-48 hours after exposure ,with 
creatinine peaking at 5-7 days.It normalises usually within 7-10 
days⁽¹⁹⁾.CIN is the third most common hospital acquired renal failure. 
PATHOGENESIS OF CIN 
 
 
 
 
 
 
 
 
 
Figure 1 Overview of the factors involved in the pathogenesis of CIN NO=nitric oxide, OH⁻ = 
hydroxyl radical, O⁻₂  Superoxide radical, PaO2 = arterial oxygen pressure. 
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               The pathogenesis of CIN is thought to be multifactorial and the 
exact mechanism is still not certain.It is said to be dependent on the 
free radicals produced  in the renal medulla’s acidic environment . The 
hyperosmolar stress  while using certain contrast agents stimulate the 
production of reactive oxygen species leading to direct cytotoxicity and 
renal tubular and glomerular cells apoptosis⁽²⁰⁻²²⁾. 
              Many animal studies have shown that there is constriction of 
the vasa recta related to contrast media seen in the outer medulla 
associated with a decline in the blood flow to the renal medulla, 
filtration rate in the glomeruli, velocity of the erythrocytes and  the 
oxygen tension, with an incline in the aggregation of erythrocytes. 
There is also an elevated adenosine, endothelin and free radical 
induced constriction of blood vessels and decreased nitric 
oxide,prostaglandin induced dilatation of blood vessels leading to 
ischeamia in the inner portions of outer medulla, where high oxygen is 
needed. Immunological etiologies have been proved as well⁽³⁰⁻³²⁾. 
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Figure 2 Proposed role of endothelin 1 in the development of 
CIN. (ET1: Endothelin 1, ETA: Endothelin A receptor, ETB: Endothelin B 
receptor, RCBF: renal cortical blood flow, RMBF: renal medullary blood 
flow, NO: nitric oxide, PG: prostaglandins, DM: diabetes mellitus, CIN: 
contrastinduced nephropathy  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Increased endothelin B causing insufficient Nitric oxide, 
insufficient prostaglandin level leading to decreased renal medullary 
blood flow , finally leading to the incidence of CIN. 
SUFFICENT NO  
SUFFICIENT PG 
NO RENAL FAILURE  
DM OR ANY OTHER 
SUSCEPTIBILITY 
INSUFFICIENT NO 
INSUFFICIENT PG 
RENAL FAILURE  
DM OR OTHER  
SUSCEPTIBILITY 
17 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 STRUCTURE OF GLOMERULUS 
The structure of the glomerulus where the direct toxic effect on renal 
tubules and the vasocontrictive effect on renal vessels after the 
exposure to contrast media takes place. 
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Renal disease due to atheroembolism can also lead to worsening 
of renal function ,post contrast study.Hence it should also be 
considered as one of the cause for post contrast renal function 
deterioration⁽³³⁾. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 : Explaining the role of osmalality of the contrast media 
in the pathogenesis of CIN  
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              The osmolality of the contrast media has been proved to have 
some role in the pathogenesis of CIN , as evidenced by many clinical 
and experimental studies⁽³⁴⁾.Contrast media given intravenously is 
shown to have lesser adverse effects than given intra-arterially. Also 
the amount needed is smaller with the intravenous route when 
compared to the other and also the osmolality of the media gets 
decreased in the circulation before it reaches the kidney ⁽³⁵⁾.There is a 
relationship between osmolality and that of viscosity of the agent 
used.Contrast media having increased osmolality than that of plasma, 
increases the fluid viscosity, and thus elevating  the resistance to the 
flow within the renal tubules⁽³⁶⁾.The viscosity in the tubular fluid is 
isotonic at an osmolality of 300 mOsm/L and it is lesser than the 
plasma viscosity⁽³⁶’³⁷⁾.The agents which have a lower osmolality 
actually  have an osmolality 2-3 times more than the osmolality of 
plasma⁽³⁵⁾.High osmolar agents decreases the red blood cells 
deformability , thus the stiffness of red blood cells is increased and thus 
the flow of red blood cells through the capillaries more 
difficult⁽³⁵’³⁶⁾.Making the red blood cells more deformed, with 
dilatation of systemic vessels , constriction of intrarenal vessels , and 
direct toxic effects on renal tubules are all seen with contrast agents 
20 
having an osmolality more than the blood⁽³⁴⁾.Patients having  diabetes 
associated with renal failure are at increased risk for CIN due to 
decrease in endogenous vasodilators such as nitric oxide and 
prostaglandins, leading to decrease in renal blood flow and GFR ⁽³⁴’³⁸⁾. 
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 Flow chart of mechanisms linking fluid osmolarity to renal damage 
GFR - glomerular filtration rate 
PHYSIOCHEMICAL CHARACTERS OF CONTRAST AGENTS 
Contrast media used are classified into high-osmolar, low –
osmalar, and iso-osmalar contrast agents.The toxicity of contrast media 
are defined by their osmolality,viscosity and chemotoxicity. The most 
commonly used media for contrast for contrast imaging procedures 
and interventions is the contrast which is iodinated. 
Contrast media with high osmolality (HOCM) are attached with a 
sodium atom ionically and they give two osmotic particles on 
dissociation in plasma. They have iodine particles which are three in 
number  per two osmotic particles(1.5:1). 
Because of high osmolality  (1500-2200 mOsm) when compared 
to Plasma (300 mOsm), they have decreased tolerability and increased 
adverse reactions. 
Second generation contrast media with low osmolality (LOCM) 
carry iodine particles which are three in number per one osmotic 
particle (3:1 ratio).They are non-ionic, since they have covalent 
bonding.They have a  osmolality which is lower (600-900 mOsm), since 
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the covalent bonds don’t  usually dissociate in plasma and thus 
producing a fewer osmotically active particles. 
The iso-osmolar contrast media (IOCM) are non-ionic dimers 
having six iodine particles per  osmotic particle (6:1ratio). They have a 
osmolality (300 mOsm) similar to plasma. 
Examples: 
Ionic , high osmolar monomers  –  Diatrizoate, Metrizoate, 
                                                                     Ioxithalamate, Iothalamate  
Ionic, low osmolar dimmers  - Ioxagate. 
Nonionic, low osmolar monomers- Iopamidol, Iomeprol,  
                                                                     Iopromide, Iohexol 
Nonionic, iososmolar dimmers -  Iodixanol 
 
STRUCTURES OF THE CONTRAST AGENTS USED 
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                 Osmolality is dependent on the number of particles of solute 
dispersed in the solution and radioopacity on the iodine concentration 
in the solution⁽³⁹’⁴⁰⁾. Osmolality can be reduced by a decrease in the 
number of iodine or by using nonionic media.  
Compound Iodine atoms Particles Ratio 
Ionic monomers 3 2 1,5 
Non ionic monomers 3 1 3,0 
Ionic dimers 6 2 3,0 
Non ionic dimers 6 1 6,0 
 
        In coronary angiography or percutaneous coronary intervention, 
Jo et al study which was a randomized study done prospectively 
showed that 10 out of 164 patients(6.1%) in the iososmolar contrast 
media had CIN when compared with the low osmolar contrast group 
where 18 out of 117 patients (15.4%) developed CIN⁽⁴¹⁾.Solomen study 
revealed that the incidence of CIN was mostly in patients who received  
iohexol than those who received iodixanol or iopamidol⁽⁴²⁾.It has been 
shown that the iososmolar contrast media have lower nephrotoxic 
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properties when compared to the low-osmolar media in a high risk 
population in the NEPHRIC study⁽⁴³⁾. 
ADVERSE RECTIONS TO CONTRAST AGENTS 
ACUTE ADVERSE EFFECTS 
Allergic like reactions 
       Allergic like reactions to injected contrast media develop in a 
similar manner to that of other drugs and allergens, but it comes under 
anaphylactoid, allergy-like or idiosyncratic since an antigen –antibody 
cannot be identified. It is not dependent on the dose and the 
concentration of the contrast media used. Treatment is like any other 
allergic reaction⁽⁴⁴’⁴⁵⁾. 
Physiological reactions 
          Physiological reactions are dose and concentration dependent. 
Cardiac arrhythmias, decreased contractility of the myocardium, 
cardiogenic pulmonary edema, and seizures are serious physiological 
reactions to iodinated contrast media and are very rare. These effects 
are attributed to the hyperosmolality of the contrast media and / or 
functional hypocalcemia due to calcium binding. Cardiac related 
adverse effects are more during intra-arterial than during intravenous 
injection of iodinated contrast media. And it is observed more in 
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patients with underlying cardiac disease⁽⁴⁶’⁴⁷⁾.Non cardiogenic 
pulmonary edema has also been very rarely reported⁽⁴⁸⁾. 
             Vasovagal reactions as evidenced by hypotension and 
bradycardia are relatively quite common probably due to increased 
vagal tone from the central nervous system. Also there is suppressed 
sinoatrial and atrioventricular nodal activity, atrioventricular 
conduction inhibition along with vasodilatation of the peripheral 
vascular system. Most vagal reactions are usually mild and self-limited. 
Patients should be monitered carefully until they recovers completely. 
                 Nephrotoxic effects in the form of contrast induced 
nephropathy is seen and is more with patients already having existing 
renal insufficiency. 
                  Patients already having an underlying medical  problem are 
more prone for adverse reactions. Bronchospasm is more common 
with patients having bronchial asthma. Many studies have proved that 
a test dose of the contrast have no role in the reduction of incidence of 
allergic reactions and in fact increase it. It is important to note that a 
non reactor to a test dose may develop a allergic reaction to the 
standard dose of the contrast. So, test doses for predicting reactors to 
contrast media used are not generally advised⁽⁴⁹’⁵⁰⁾. 
26 
KQ – Key Questions 
Analytic Frame Work Examining Intervention to prevent CIN 
AKI – Acute Kidney injury   CKD – Chronic Kidney Disease 
RRT – Renal Replacement Therapy  ESRD  - End Stage Renal Disease 
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KQ – Key Questions 
Analytic Frame Work Comparing Benefit and Harms of Different Contrast Media  
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              A review by effective health care program was done in in Jan 
2013, where seven meta-analyses done in the  last 12 months on CIN 
were reviewed.
 
These meta-analyses focused primarily on the 
incidence of CIN by route of administration of contrast media and 
various prevention methods. Their results are varied and conflicting, 
likely due to the varied inclusion criteria. Based on the increasing use of 
contrast media, the increasing prevalence of populations vulnerable to 
CIN (i.e., people having chronic kidney disease, diabetes mellitus, or 
hypertension, and the elderly), increasing use of radiologic and 
cardiologic studies, and controversial and discrepant results from 
various prior meta analyses, a comprehensive systematic review of this 
topic will be extremely valuable to clinicians who wish to minimize the 
risk of CIN in patients undergoing imaging studies. The following two 
analytical framework charts  were used in the study which compared 
the benefits and harms of different contrast media used and also the 
interventions to prevent CIN.  
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RISK FACTORS FOR CIN 
The factors that increase the occurance of CIN are either related 
to the patient or the contrast media used or the procedure related⁽⁵¹’⁵³⁾ 
PATIENT RELATED RISK FACTORS 
OLDER AGE 
 
        Explanations are attributed to the age related changes like 
increase in vasoconstrictive effect than the vasodilatory effect, vascular 
access difficulty and calcification of the vessels increasing the 
requirement of the contrast media used.And also the presence of 
associated renovascular disease. 
GENDER 
            Females are an independent predictor of CIN explained being 
the ovarian hormones affecting the renin-angiotensin system and the 
renal blood flow. 
PREEXISTING RENAL DISEASE 
           Chronic kidney disease usually have a decreased vasodilatory 
response which has a role in the development of CIN. Also the 
clearance of contrast media is delayed in patients with preexisting 
renal disease. 
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DIABETES MELLITUS 
                   In patients with diabetes have alteration of Nitric-oxide 
mediated vasodilatation and there is reduction of renal outer 
medullary oxygen⁽⁵⁴⁾.Endothelial dysfunction is also seen in patients 
with diabetes and chronic kidney disease. Diabetic nephropathy is an 
important risk factor for CIN. 
 LEFT VENTRICULAR DYSFUNCTION 
            Decreased left ventricular ejection fraction and congestive heart 
failure (New York Heart Association class iii or iv ) are also shown to 
have some role in the development of CIN⁽⁵⁴’⁵⁵⁾.  
HYPERTENSION 
         In hypertension, the intra renal expression of renin angiotensin 
system or nitric oxide which are vasoactive substances contributes to 
the emergence of hypertension as a risk factor . 
ANGIOTENSIN CONVERTING ENZYME INHIBITORS 
        They have a potential in the reduction of renal function ,hence 
considered as a risk factor in the development of CIN as evidenced in 
some studies⁽⁵⁷⁾.It is important to check for the use of ACE inhibitors 
before coronary angiography. 
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NEPHROTOXIC DRUGS 
          Drugs which are toxic to kidney and the drugs which antagonise 
the vasodilatory effects of prostaglandins make the kidneys more 
prone to the toxic effects of contrast media. Sulphanamides, 
Aminoglycosides, Cyclosporin A,and Cisplatin are some of the drugs 
most commonly witnessed with nephrotoxicity,more when combined 
with frusemide.Non selective NSAIDS and selective COX-2 inhibitors 
increase the vasoconstrictive effects of contrast media by decreasing 
the vasodilatory prostaglandins⁽⁵⁸’⁵⁹⁾. 
METFORMIN 
           A decrement in the renal function after contrast media would 
affect the clearance of metformin, leading to development of lactic 
acidosis. 
HYPERCHOLESTEROLEMIA 
        Hypercholesterolemia promotes the development of CIN by 
decreasing the production of nitric oxide. 
HYPERURICEMIA 
       Tubular obstruction by uric acid has been found to have a role in 
the development of CIN. There is increased production of reactive 
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oxygen species, endothelin -1, stimulated renin-angiotensin system, 
and an inhibited nitric oxide  ,all are involved in the development of 
CIN⁽⁶⁰⁾. 
HYPOVOLEMIA 
         Decreased renal perfusion and decreased effective circulating 
volume stimulate renal vasoconstriction after exposure to contrast 
media. And the toxic effects of contrast media may get aggravated in 
the presence of hypovolemia. Also there is increased sodium 
reabsorption because of hypovolemia leading to vasoconstrictive 
stimuli depriving oxygen in the medulla⁽⁶¹’⁶²⁾. 
LOW SERUM ALBUMIN LEVEL 
          Low serum level alters the function of endothelium, increases the 
renal vasoconstrictive effect, decreases the production and release of 
nitric oxide⁽⁶³⁾. 
HEMATOCRIT LEVEL  
 
             When there is decreased level of hematocrit, there is increased 
incidence of CIN due to anemia induced deterioration of renal 
ischeamia. Each 3% decrease in hematocrit from the baseline resulted 
in a increase in the incidence of CIN in patients with and without 
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chronic kidney disease (11 and 23 % respectively).This is shown in a 
prospective study by Nikolsky et al⁽⁶⁴⁾.Dangas et al also showed that 
the hematocrit level is one of the predictors for the development of 
CIN in patients with chronic kidney disease⁽⁶⁵⁾. 
MULTIPLE MYELOMA 
           Patients having multiple myeloma are considered to be a risk 
factor for the development of CIN. The mechanism proposed is that in 
multiple myeloma , high amount of protein in the tubular lumens of 
the kidneys along with concomitant load due to contrast media might 
cause a obstructive nephropathy. The pathomechanism of this that 
there is precipitation of contrast agents ,along with Tamm-Horsfall 
proteins and other abnormal proteins. Also because of the 
concomitant occurance of hyperuricemia, hypercalcemia, dehydration, 
amyloidosis and light chain nephropathy in multiple myeloma, patients 
with multiple myeloma are at increased risk of CIN when compared 
with others having contrast administration. 
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OTHER FACTORS RELATED TO THE PATIENT 
1. Metabolic syndrome 
2. Impaired fasting glucose and hypertriglyceridemia 
3. Hypotension 
4. Sepsis 
5. Cirrhosis 
6. Pulmonary Edema. 
7. Acute myocardial infarction 
8. Renal transplantation 
9. Multiple coronary vessel involvement 
10. Peripheral vascular involvement 
11. Renal artery stenosis 
          
PROCEDURE AND CONTRAST MEDIA RELATED RISK FACTORS 
 
1. Increased total dose of contrast media 
2. High osmolality of the contrast media 
3. High viscosity of the contrast media 
4. High ionic content of the contrast media 
5. Intra arterial injection of the contrast media 
35 
6. Urgent or emergency procedures 
7. Intraaortic ballon pump usage 
8. Intervention with bypass graft and when reperfusion is delayed 
9. The interval between contrast using  procedures is less than two 
days  
 
Generally factors contributing to the development of CIN are 
divided into non modifiable and modifiable risk factors 
 
Non modifiable risk factors 
 
Older age  
Patients with pre existing renal dysfunction 
Diabetus mellitus 
Congestive cardiac failure with low ejection fraction 
Acute myocardial infarction 
H/o cardiogenic shock 
H/o renal transplant 
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Modifiable risk factors 
 
 
Volume of contrast media used 
Osmolality of the contrast media used 
Hemodynamic instability 
Dehydration 
Use of frusemide 
Use of nephrotoxic drugs 
Anemia and procedural blood loss 
Repeat administration of contrast agent within three weeks 
 
PREVENTION OF CIN 
         For the prevention of CIN either pharmacological or non 
pharmacological methods can be used. 
PHARMACOLOGICAL  METHODS 
HYDRATION 
        Adequate hydration before the procedure is very important in the 
maintenance of renal function.Thus maintaining adequate intravascular 
volume for renal perfusion and also preventing the occurrence of 
hypotension is important. There are studies regarding hydration in the 
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form of bolus versus continuous ,the later being found better.And oral 
versus intravenous form, the intravenous form being found better.  
N-ACETYL CYSTEINE (NAC) 
 
 
 
 
NAC may reduce  vasoconstriction and oxygen free radical 
generation after contrast media exposure. 
 
        The APART (Acetylcysteine to prevent Angiography –related renal 
tissue injury) trial showed that N-acetylcysteine reduced the 
occurrence of CIN compared with the placebo group⁽⁶⁶⁾.However, 
another study by Briguori et al failed to show the difference in the 
occurrence of CIN between the patients taking N-acetylcysteine with 
hydration and patients given hydration alone⁽⁶⁷⁾. 
 
A large multicentre randomised, placebo controlled ACT 
(Acetylcysteine for contrast induced nephropathy) trial, did not show 
the protective role of N-acetylcysteine in prevention of CIN⁽⁶⁸⁾. 
 
38 
DOPAMINE 
            Dopamine in a low dose usually has a vasodilatory effect on the 
blood vessels of the kidney and hence it has a protective effect on the 
kidneys. But ,dopamine does not show a similar effect on renal 
function taking contrast media⁽⁶⁹’⁷⁰⁾.  
FENOLDOPAM 
          Fenoldopam is a selective dopamine -1 receptor agonist that 
increases renal blood flow.Hence considered to decrease the incidence 
of CIN. However, the multicentre randomized CONTRAST trial did not 
show a reduction in the incidence of CIN with the treatment of 
fenoldopam⁽⁷¹⁾. 
THEOPHYLLINE AND AMINOPHYLLINE 
         Theophylline and aminophylline which are non specific adenosine 
(A1) receptor antagonists may decrease the blood flow to the kidneys 
and glomerular filtration rate stimulated after exposure to contrast 
media. In a study by Huber et al, prophylactic theophylline 200 mg 
given intravenously decreased the incidence of CIN when compared 
with the placebo. However, other studies did not reveal a relation 
between the prophylactic theophylline and the incidence of CIN⁽⁷²’⁷³’⁷⁴⁾. 
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CALCIUM CHANNEL BLOCKER 
 
         They have a favourable outcome on renal hemodynamics like 
reversal of renal vasoconstriction,decrease in renal hypertrophy, 
decrease in free radical formation,reduction of calcium overload 
produced by toxic or ischemic stimuli.In a study that included 35 
patients, glomerular filtration rate was preserved in patients who 
received nitrendipine compared to patients who did not receive in 
whom it was decreased⁽⁷⁵⁾.However, in three other studies, where the 
effect of calcium channel blockers was studied did not show a 
difference⁽⁷⁶⁻⁷⁸⁾. 
ACE INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS 
          ACE inhibitors and angiotensin receptor blockers decrease the 
constriction of afferent arterioles ,also decrease medullary ischemia 
and thus decrease the incidence of CIN in patients undergoing contrast 
using procedure.Captopril was used in a study which included a small 
group of 71 patients with diabetes mellitus in whom coronary 
angiography was done.The  filtration rate in the glomeruli increased in 
patients to whom captopril was given but decreased in patients to 
whom it was not given⁽⁷⁹⁾.However, this was not supported  in another 
retrospective study, where the use of ACE inhibitors proved to increase 
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the incidence if CIN⁽⁸⁰⁾.Therefore, there is not enough studies or 
support to approve or disprove the use of ACE inhibitors or angiotensin 
receptors before the exposure to contrast in patients who are at high 
risk of developing CIN. 
ATRIAL NATRIURETIC PEPTIDE 
       Atrial natriuretic petide was used by Kurnik et al in three different 
doses for  the prevention of CIN. It did not reveal any evidence of 
prevention⁽⁸¹⁾. 
PROSTAGLANDINS E1 
         A study investigated the effect of prostaglandins E1 given 
intravenously in three different doses, since the prostaglandins cause a 
change in physiologic vasoconstriction/vasodilatation balance which is 
beneficial in decreasing the incidence of CIN. All the three group of 
patients showed less incline in serum creatinine when compared to the 
placebo group after the contrast using procedure⁽⁸²⁾.  
STATINS 
        In two retrospective studies, pretreatment with statins was 
evidenced by decreased incidence of CIN⁽⁸⁴⁾. However, another 
prospective study in 247 patients with chronic renal insufficiency did 
not support this evidence⁽⁸³⁾. 
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ASCORBIC ACID 
       A recent randomised trial evidenced that the use of ascorbic acid 
was shown to have a reduction in CIN by 62% in patients with renal 
insufficiency undergoing coronary angiography⁽⁸⁵⁾  
ENDOTHELIN RECEPTOR BLOCKERS 
        Oldroyd et al  study studied the effect of bosentan, an oral 
endothelin antagonist, for decreasing the deterioration of renal 
function following contrast exposure in animal models⁽⁹³⁾.In Wang et al 
study, the patients were taken for cardiac angiography with a mixed 
endothelin A and B antagonist versus placebo.Also all the patients were 
hydrated with saline.The increase in creatinine  from the baseline value 
is found to be more in patients who were treated compared with those 
not treated.(56% versus 29%).This is observed in both diabetic and non 
diabetic patients⁽⁹⁴⁾. 
TRIMETAZIDINE 
             The mechanism behind using trimetazidine in the reduction of 
renal injury is by decreasing the adenosine tri phosphate intracellularly 
and thereby increasing the metabolism of glucose by blocking the 
42 
metabolism of fatty acid.Hence, trimetazidine with hydration was tried 
and it was found to be effective when compared with the placebo. 
More studies are required regarding formulating a protocol. 
ANISODAMINE 
               It is a belladonna alkaloid from a Chinese herb and it is a 
blocker of M-choline. It is found to increase the ischemic tolerance. 
PLATELET GLYCOPROTEIN IIb/IIIa RECEPTOR INHIBITORS 
              These drugs – abciximab, eptifbatide or tirofiban were found to 
increase the blood flow to the kidneys which were decreased by the 
contrast agents and also they increase the perfusion to the kidneys by 
decreasing the aggregation of platelets.  
METHODS USED DURING THE PROCEDURE TO DECREASE THE 
EXSPOSURE TO CONTRAST WHICH IS IODINATED 
                Methods for decreasing the amount of contrast used during 
the contrast using procedures are important in that they decrease the 
adverse effects with the use of contrast agents proportional to the 
volume of contrast used, but are not much studied. 
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           Diluting the contrast agent used is an effective and useful way in 
decreasing the dose of contrast media used.The dilution of 1:3 to 1:5, 
that is the ratio of contrast to saline when used in the procedures 
involving the extremities, could produce effective diagnostic imaging 
results.When used in the abdomen, dilution of 1:2 was sufficient to 
give the results.  
          Using digital software for enhancing the images such as image 
stacking software can further increase the quality of the images 
especially in the extremities. Also the bolus chasing technique can 
guide us with a single injection.  
          Another important technique in decreasing the volume of 
contrast used is the placement of the catheter. The amount of contrast 
needed will be decreased when we place the catheter nearer to the 
target. 
        Various other methods used to decrease the amount of contrast 
used include CO2 angiography, biplane angiography to get multiple 
images with one injection.We can also use rotational CT  and 
intravascular ultrasound to procede the procedures and thus 
decreasing the volume of contrast used.  
.  
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HEMODIALYSIS 
 
         Contrast agents which are iodinated are dialyzable easily.The 
contrast media are cleared from the plasma at the rate of 50-70 
mL/min, approximately about 80% are cleared from the plasma in 
about  four to five hours of hemodialysis. Many studies done to see the 
effect of hemodialysis, in patients already having chronic kidney 
disease after they got exposed to contrast media, to decrease the 
effect on renal function, did not show any promising effect. Also 
studies done to see the effect of prophylactic hemodialysis, which was 
done just after patient got exposed to contrast did not decrease the 
incidence of CIN or other adverse effects⁽⁸⁶’⁸⁷⁾.But in one study, where 
patients where given adequate hydration versus hydration and 
hemodialysis immediately after contrast exposure. Here, prophylactic 
hemodialysis showed less creatinine increase and decreased 
requirement of further renal replacement therapy⁽⁸⁸⁾. 
HEMOFILTRATION 
       In one prospective study in patients with already existing renal 
insufficiency , hemofiltration done before and after contrast using 
procedure, was compared with hydration.Patient who underwent 
hemofiltration alone showed  decreased incidence of CIN, decreased 
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requirement of  renal replacement therapy, decreased mortality both 
in hospital and also in one year⁽⁸⁹⁾.  
TARGETED RENAL TREATMENT 
                Here the therapeutic drugs are given to the kidneys using a 
separated infusion machine. Here there is increased and persistant 
levels of medicines in the kidney and thus decreasing the adverse 
effects. There was a study done in 285 patients who were at increased 
chance for getting CIN, where fenoldopam was given into the renal 
arteries ,were found to have a lower incidence of CIN. 
HYPOTHERMIA 
                The incidence of renal damage post contrast study in patients 
with neurological damage and association with hypothermia was 
studied in a trial of 128 patients with a maintenance of core 
temperature of 33 to 34 degree centigrade versus normal temperature, 
found that there is no variation in the occurrence of renal damage 
between normothermic and hypothermic patients. 
ISCHEMIC PRECONDITIONING 
               It means that by creating brief intermittent ischemia in the 
nontarget organs vascular bed, and hence protecting the target organ. 
The method  starts before the contrast using procedure with four 
46 
cycles of alternating five minutes inflation and five minutes of deflation 
of blood pressure cuff .The result in the form of elevation of serum 
creatinine from the baseline value within 48 hours was taken.The 
incidence of renal injury was found to be less in the persons who 
underwent ischemic preconditioning. Serum cystatin and urinary NGAL 
were also found to be less in the limb maintained with ischemic 
preconditioning. The possible explanations for the result could be due 
to  inflammatory and anti-inflammatory genes involved and also there 
could be some vasodilation involved. 
 
ALTERNATIVE IMAGING STUDIES 
 
              Alternative methods of diagnostic studies without iodinated 
contrast media should be considered in patients with risk factors such 
as ultrasonography, scintigraphy, CT without contrast,and Magnetic 
resonance imaging. The use of non enhanced CT in the diagnosis of 
clinical cases should be thought of before subjecting them to contrast 
exposure.  
Summary of some of the Preventive methods used for the 
prevention of CIN, both pharmacological and Non pharmacological. 
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Preventive strategies Efficacy 
Pharmacological strategies 
Hydration Beneficial 
Sodium bicarbonate Inconsistant data 
Furosemide May be harmful 
N acetyl cysteine Inconsistant data 
Mannitol  May be harmful 
Fenoldapam No benefit 
Dopamine No benefit 
Statins May be beneficial 
Atrial natriuretric peptide No benefit 
Theophylline/Aminophylline Inconsistant data 
Calcium channel blockers Inconsistant data 
ACE inhibitors/Angiotensin 
receptor blockers 
Inconsistant data 
Prostaglandin E1 May be beneficial 
Non pharmacological strategies 
Hemodialysis Inconsistant data 
Hemofiltration May be beneficial 
Benephit infusion system May be beneficial 
Renal guard system May be beneficial 
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GUIDELINES USED FOR PREVENTING CIN 
HYDRATION WITH SALINE⁽⁹⁰⁾ 
              Calculation of intravenous fluid used = 1ml/kg/hr (maximum 
100ml/hr) 12 hours before and 12 hours after contrast (totally 24 hours 
as infusion ) 
              In patients with congestive heart failure or having decreased 
ejection fraction <40%,- 0.5 ml/kg/hr (maximum 50 ml/hr) 12 hours 
before and 12 hours after contrast (totally 24 hours infusion ) can be 
given. 
For  emergency procedure 
         Bolus of around 500-1000ml of fluid before the procedure should 
be given.Hydration should be done during the procedure and 
continued 12 hours post procedure  (according to the clinical status) 
GUIDELINES FOR USING BICARBONATE⁽⁹¹⁾ 
Intravenous fluid in the form 5%Dextrose with 150 meq of 
sodium bicarbonate at the rate of 3ml/kg stat dose one hour before 
the procedure and 1ml/kg /hour (maximum 100ml/hr ) during and for 6 
hours after the procedure. But in patients with diabetes mellitus sterile 
water can be used in the place of 5% Dextrose water . 
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GUIDELINES FOR USING N-ACETYL CYSTEINE⁽⁹²⁾ 
If patients are taking orally, 600-1200 mg capsules are given 
every 12 th hourly ,totally for 4 doses.It is better to give 2 doses before 
the procedure and 2 doses after the procedure. 
If patients are on feeding tubes or nasogastric tubes, N-acetyl 
cysteine is given in the form of solution as 3ml of 20% solution which 
contains 600-1200 mg every 12 th hourly, for totally 4 doses. 
If the patient is taken for emergency procedure, one dose of N-
acetyl cysteine should be given before the procedure and 3 doses post 
procedure is given. 
Intravenous form of N-acetyl cysteine can also be given in 
patients in high risk patients who cannot be given orally, in the dose of 
600-1200 mg IV one dose over a period of 15 minutes, 600-1200mg 
every 12 th hourly for 4 doses. 
            Other drugs which can also be given are 
• Ascorbic acid in the dose of 3gm intravenously over 2 hours 
before the procedure and 2 gm x 2 doses following the 
procedure. 
• Aminophyline 300 mg intravenously given over a period of 1 
hour before the procedure. 
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CLINICAL FEATURES AND INVESTIGATIONS IN CIN           
Epithelial cells in urine, calcium oxalate and urate crystals in 
urine are non specific findings seen in contrast induced nephropathy. 
Low urinary sodium and fractional excretion of sodium are considered 
as distinctive features of CIN , but they are not shown to be specific for 
CIN. 
          CIN is usually non oliguric and asymptamatic with a transient 
decrease in renal function. The value of serum creatinine rises within 
24 hours post contrast procedure with attaining peak in 3- 5 days and 
usually returns to baseline in 10- 14 days. Rare situations are there 
where hemodialysis is needed for oliguric acute renal deterioration. 
This is manifested as oliguria (less than 400 ml of urine volume in 24 
hours), within 24 hours of  post contrast exposure and persists for 2 – 5 
days.Mortality and morbitidy are proportionately higher in these group 
of patients who had undergone hemodialysis when compared with the 
patients who have non oliguric renal failure.   
                Treatment of CIN begins with the early recognition of renal 
dysfunction ,post study. In patients with high risk factors, serum 
creatinine should be monitored before the procedure and daily for 5 
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days post procedure. Once CIN is diagnosed, further treatment is 
similar to that of acute renal failure resulting from any other 
cause.Monitering of serum electrolytes for the presence of 
hyperkalemia, hyponatremia, hypocalcemia, hypermagnesemia, 
hyperphosphatemia and metabolic acidosis is required as in patient 
.Intake- output of fluids, with proper nutritional support  are necessary 
until serum creatinine value returns to baseline. Hemodialysis which is 
temporary will be required in severe cases. A minority of patients who 
are not responding to conservative line of management may require 
permanent dialysis or renal transplantation.   
 To assess the combined risk of multiple variables on renal 
function, a simple CIN risk score was developed for assessing the risk of 
CIN and the risk of dialysis in patients undergoing PCI. The risk factors 
included were hypotension, IABP, CHF, Age >75 years, Anemia, 
Diabetes, Volume of contrast media, Serum creatinine or eGFR. The 
assessment of the risk for CIN post-PCI in a simple way with the readily 
available information makes widespread use of this risk score for both 
clinical and investigational purpose. 
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Risk prediction score for the development of contrast 
induced nephropathy and renal failure requiring dialysis 
Risk factors           Integer score 
Hypotension          5 points 
Use of intra-aortic balloon bump  5 points 
Congestive heart failure      5 points 
Age >75 years         4 points 
Anemia          3 points 
Diabetic mellitus       3 points 
Volume of contrast media  1 point for each 100 ml used 
S.creatinine >1.5 mg/dl      4 points 
Or 
eGFR  60ml/min/1.73 m2 
      2 points for 40-60 
      4 points for 20-40 
      6 points for  <20 
Risk assessment 
Risk score  Risk of CIN  Risk of dialysis 
 5 points   7.5%    0.04% 
6–10 points   14%    0.12% 
11–16 points  26.1%   1.09% 
16 points   57.3%   12.6% 
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IMPLICATIONS OF CIN 
                   Clinical implications of renal function deterioration post 
exposure to contrast agent  were studied in many trials. A key factor in 
the identification of even a small deterioration in the renal function can 
lead to a dramatic effect on the prognosis. 
                Another study which included 19,982 patients showed that a 
smaller increase in serum creatinine was associated with increased 
mortality , increased length of hospital stay and increased cost of 
treatment. 
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                                   MATERIALS AND METHODS 
STUDY POPULATION 
The study included 102 patients who had coronary angiogram in 
the Cardiology Department in the Government Stanley Medical College 
from June2013 to August2013 . 
STUDY DESIGN 
Age and gendor of the patients noted.  
Patients were taken as hypertensives if they were already under 
antihypertensives or newly diagnosed if their blood pressure was 
above or equal to 140/90 mmHg according JNC 7 criteria. 
Patients who were already taking oral hypoglyceamics or on 
subcutaneous insulin preparations or newly diagnosed with the 
random blood sugar >200 mg /dl or with a fasting blood sugar 
>126mg/dl were noted as diabetics. 
Patients who smoke tobacco in any form irrespective of number 
of years were noted as smokers.No criteria was followed. 
           The hydration of the patient was clinically examined. No regime 
was followed for hydrating the patients if they were found to be 
dehydrated. 
55 
The drug history of the patient especially nephrotoxic drug 
intake was asked namely ACE inhibitors, Diuretics, Analgesics in the 
form of NSAIDS, and any nephrotoxic antibiotics recently for any illness 
were noted down. 
               The haemoglobin status of the patient was noted down.Patient 
was considered as anaemic if the haemoglobin level was below 12 
gms% in females and 13 gms% in males according to WHO criteria. 
               Volume of the contrast media used during the coronary 
angiogram study was between 30-50 ml.None of the study used the 
contrast media above 50 ml.The contrast used was iohexol which is 
non-ionic, water soluble contrast media which contains 17.5 gms of 
Iodine in 50ml. 
             Renal function of all patients undergoing the coronary 
angiogram were assessed with the values of serum creatinine, blood 
urea, urine routine examination and examining with the ultrasound for 
the kidney size and corticomedullary differentiation. And patients with 
altered renal parametres were not included in the study. 
               The values of serum creatinine before the angiogram was 
taken. And the serum creatinine was repeated after 48 hours of the 
study for any change in the value and noted down. 
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                The patients were under strict observation to look for any 
allergic or adverse reactions in any form during the use of the contrast 
in the study.No such reactions were seen during the study or after the 
study. 
           Patients were all informed about the study and the adverse 
reactions of the contrast used and written informed consent obtained 
before subjecting to the procedure. 
           No regime or protocol was followed before and after the study 
for preventing the incidence of CIN. And since this is an observational 
study. 
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STATISTICAL ANALYSIS 
            The datas collected from the patients were age and gendor of 
the patients ,smoking history, presence of hypertension, presence of 
diabetes mellitus, intake of ACE inhibitors, Diuretics, Non steroidal anti 
inflammatory drugs, Nephrotoxic antibiotics ,volume of the contrast 
media used, hydration status of the patient, and  hemoglobin 
percentage . 
            Descriptive statistical analysis has been carried out in the 
present study. Results on continuous measurements are presented on 
Mean ± SD and results on categorical measurements are presented in 
percentage (%). Chi-square test has been used to find the significance 
of study parameters on categorical scale between two groups. Student 
‘t’ test has been used to determine the significance between two group 
means. All analyses were two tailed and p <0.05 was considered 
significant. SPSS version 16.0 was used for data analysis.    
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OBSERVATIONS 
                 The following are the contributions made by the risk factors 
that we included in the study 
Age 
  Frequency Percent 
Age 
<75 yrs 100 98.0 
>=75 2 2.0 
Total 102 100.0 
 
Table 1 : Age distribution in the study population 
Patients below 75 years were 98% and patients more than or 
equal to 75 years were 2 % in our study 
Gender 
 Frequency Percent 
Gender 
Male 79 77.5 
Female 23 22.5 
Total 102 100.0 
 
Table 2 : Gender distribution in the study population 
Male patients participated in our study were 77.5% and females were 
22.5% 
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Smokers 
  Frequency Percent 
Smoker 
Yes 38 37.3 
No 64 62.7 
Total 102 100.0 
 
Table 3 : Smokers Distribution in the study population 
 Smokers versus Non smokers -37.3% versus 62.7% 
HT 
  Frequency Percent 
HT 
Yes 35 34.3 
No 67 65.7 
Total 102 100.0 
 
Table 4 : Hypertensive Patients in the Study population 
 
Hypertensive patients were 34.3 % and non hypertensives were 
65.7% 
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DM 
  Frequency Percent 
DM 
Yes 35 34.3 
No 67 65.7 
Total 102 100.0 
 
Table 5 : Diabetic Patients in the Study Population 
 
      Diabetic patients were 34.3% and non diabetic patients were 65.7 %  
 
                                             ACE INHIBITORS  
  Frequency Percent 
ACE inhibitor use 
Yes 33 32.4 
No 69 67.6 
Total 102 100.0 
 
Table  6 :  ACE  inhibitors users in the study Population 
 
Patients who were using ACE inhibitors were 32.4% and the 
remaining 67.6% were not using it. 
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DIURETICS  
  Frequency Percent 
Diuretics usage 
Yes 13 12.7 
No 89 87.3 
Total 102 100.0 
 
Table 7 : Diuretics users in the Study Population 
Patients using diuretics at the time of study were 12.7 % and those not 
using were 87.3% 
NSAIDS 
  Frequency Percent 
NSAID Yes 27 26.5 
No 75 73.5 
Total 102 100.0 
 
Table 8: NSAID users in the Study Population 
Patients on NSAIDS were 26.5% and who were not were 73.5% 
 
 
 
62 
NEPHROTOXIC ANTIBIOTICS 
  Frequency Percent 
Nephrotoxic 
antibiotics 
Yes 4 3.9 
No 98 96.1 
Total 102 100.0 
 
Table  9 : H/0 Nephrotoxic Antibiotics in the Study Population 
Patients with the recent history of intake of nephrotoxic 
antibiotics were found to be 3.9% and patients with the negative 
history were 96.1% 
DEHYDRATION 
  Frequency Percent 
Dehydration 
Yes 11 10.8 
No 91 89.2 
Total 102 100.0 
     
Table 10 Dehydrated Patients in the Study Population 
10.8% of our patients under study were found to be dehydrated 
and remaining 89.2% were found to be hydrated adequately. 
 
63 
Hamoglobin 
 Frequency Percent 
Anemia 86 84.3 
Non anemia 16 15.7 
Total 102 100.0 
 
Table 11 Anemia percentage  in the Study Population 
Patients with haemoglobin less than 12 gms% in females and less 
than 13gms% in males is 84.3%  and the patients who were not anemic 
were found to be 15.7% 
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INTERPRETATION OF EACH FACTOR’S CONTRIBUTION TO THE 
DEVELOPMENT OF CIN  
AGE AND CIN 
   CIN 
Total 
   Yes No 
age_75gp 
<75 yrs 
Count 22 78 100 
% within 
age_75gp 
22.0% 78.0% 100.0% 
>=75 
Count 1 1 2 
% within 
age_75gp 
50.0% 50.0% 100.0% 
Total 
Count 23 79 102 
% within 
age_75gp 
22.5% 77.5% 100.0% 
 
The proportion of CIN is higher in patients <75 years, and it is not 
statistically significant.(p value =0.402).Also our concern is the number 
of patients above 75 years who more prone for CIN contributed only 
2% of our study. Hence their contribution could not be studied. 
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SMOKERS AND CIN 
    CIN 
Total 
   Yes No 
Smoker 
Yes 
Count 10 28 38 
% within 
Smoker 
26.3% 73.7% 100.0% 
No 
Count 13 51 64 
% within 
Smoker 
20.3% 79.7% 100.0% 
Total 
Count 23 79 102 
% within 
Smoker 
22.5% 77.5% 100.0% 
 
Contribution by smokers to the development of CIN was 26.3% with a p 
value of 0.625 which is statiscally not significant 
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DM AND CIN 
   CIN 
Total 
   Yes No 
DM 
Yes 
Count 12 23 35 
% within DM 34.3% 65.7% 100.0% 
No 
Count 11 56 67 
% within DM 16.4% 83.6% 100.0% 
Total 
Count 23 79 102 
% within DM 22.5% 77.5% 100.0% 
 
Of the 35 Diabetic patients in our study 12 patients were found 
to have CIN which corresponded to the percentage of  34.3 % with a 
significant p value of 0.049 and it is statiscally significant.This is the risk 
factor which contributed much to the development of CIN in our study. 
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HT AND CIN  
   CIN 
Total 
   Yes No 
HT 
Yes 
Count 8 27 35 
% within HT 22.9% 77.1% 100.0% 
No 
Count 15 52 67 
% within HT 22.4% 77.6% 100.0% 
Total 
Count 23 79 102 
% within HT 22.5% 77.5% 100.0% 
 
The incidence of CIN in the hypertensive patients in our study is 
22.9% with a p value of 1.000, which is statiscally not significant. 
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ACE INHIBITORS AND CIN 
 
   CIN 
Total 
   Yes No 
ACE 1 
Yes 
Count 9 24 33 
% within ACE 1 27.3% 72.7% 100.0% 
No 
Count 14 55 69 
% within ACE 1 20.3% 79.7% 100.0% 
Total 
Count 23 79 102 
% within ACE 1 22.5% 77.5% 100.0% 
 
ACE inhibitors users in our study group were around 32.4 % and 
their contribution to CIN is around 27.3% with a p value of 0.455, which 
is statiscally insignificant. 
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   DIURETICS AND CIN 
 
   CIN 
Total 
   Yes No 
DIUR 
Yes 
Count 3 10 13 
% within DIUR 23.1% 76.9% 100.0% 
No 
Count 20 69 89 
% within DIUR 22.5% 77.5% 100.0% 
Total 
Count 23 79 102 
% within DIUR 22.5% 77.5% 100.0% 
 
Out of the 12 patients of 102 patients who were using diuretics 
at the time of study, the incidence of CIN is 23.1% with a p value of 
1.000  which is statiscally insignificant. 
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NSAIDS AND CIN 
 
   CIN 
Total 
   Yes No 
NSAID 
Yes 
Count 5 22 27 
% within NSAID 18.5% 81.5% 100.0% 
No 
Count 18 57 75 
% within NSAID 24.0% 76.0% 100.0% 
Total 
Count 23 79 102 
% within NSAID 22.5% 77.5% 100.0% 
 
 
The number of patients who were using NSAIDS at the time of study 
were 26.5 % and their contribution to the incidence of CIN is18.5% with 
a p value of 0.789, which is statiscally insignificant. 
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NEPHROTOXIC ANTIBIOTICS USAGE AND CIN 
 
 
   CIN 
Total    Yes No 
NEP AB Yes Count 2 2 4 
% within NEP AB 50.0% 50.0% 100.0% 
No Count 21 77 98 
% within NEP AB 21.4% 78.6% 100.0% 
Total Count 23 79 102 
% within NEP AB 22.5% 77.5% 100.0% 
 
 
The percentage of patients who were on nephrotoxic within recently 
before the procedure were only 3.9% and the contribution by their 
usage to CIN is 50.0% with a  value of 0.218 which is statiscally 
insignificant. 
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DEHYDRATION AND CIN 
  
   CIN 
Total    Yes No 
DeHy Yes Count 3 8 11 
% within DeHy 27.3% 72.7% 100.0% 
No Count 20 71 91 
% within DeHy 22.0% 78.0% 100.0% 
Total Count 23 79 102 
% within DeHy 22.5% 77.5% 100.0% 
 
 The percentage of dehydrated patients in our study were 10.8% 
and the contribution by them to the ocurrance of CIN is 27.3 % with a p 
value of 0.708 which is statiscally insignificant. 
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HEMOGLOBIN IN MALES AND CIN 
Gender 
CIN 
Total Yes No 
Male hb_group Anemia Count 19 48 67 
% within 
hb_group 
28.4% 71.6% 100.0% 
Non anemia Count 1 11 12 
% within 
hb_group 
8.3% 91.7% 100.0% 
Total Count 20 59 79 
% within 
hb_group 
25.3% 74.7% 100.0% 
 
The incidence of CIN in male patients who were anemic is found to be 
28.4% out of 77.5% male patients studied with a p value of 0.277 which is 
statiscally not significant. 
HEMOGLOBIN IN FEMALES AND CIN 
Gendor 
CIN 
Total Yes No 
Female hb_grou
p 
Anemia Count 3 16 19 
% within 
hb_group 
15.8% 84.2% 100.0% 
Non 
anemia 
Count 0 4 4 
% within 
hb_group 
.0% 100.0% 100.0% 
Total Count 3 20 23 
% within 
hb_group 
13.0% 87.0% 100.0% 
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The incidence of CIN is 15.8% out of 22.5% female patients 
studied with a p value of 1.000 which is not statiscally significant. 
 
HEMOGLOBIN AND CIN 
 
   CIN 
Total 
   Yes No 
hb_group 
Anemia 
Count 22 64 86 
% within hb_group 25.6% 74.4% 100.0% 
Non 
anemia 
Count 1 15 16 
% within hb_group 6.2% 93.8% 100.0% 
Total 
Count 23 79 102 
% within hb_group 22.5% 77.5% 100.0% 
 
The percentage of patients who were anemic according to WHO 
criteria in both males and females were around 84.3 %,with the 
contribution to the ocurrance of CIN by males to 24.8% and by the 
females to 15.8% and the combined contribution being 25.6% with a p 
value of 0.112.And this is statiscally insignificant. 
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DISCUSSION 
 
Our study showed the incidence of contrast induced 
nephropathy in patients undergoing contrast using procedure coronary 
angiogram with normal renal function in our hospital. 
            The incidence of contrast induced nephropathy  in our study was 
found to be 22.5%. 
           The patients who underwent study were with normal renal 
function. The patients with elevated renal parameters were excluded 
from the study. Hence the incidence of CIN in patients with already 
existing renal function could not be studied. Also since no prophylactic 
measures were followed in our study , the effects of any prophylactic 
measures could not be studied. 
           McCullough PA et al study showed an elevation of serum 
creatinine in 14.5% of patients who had coronary artery imaging 
studies ⁽¹⁾. Iakovou I et al study showed elevation of serum creatinine 
in 16.5%  of patients⁽⁸⁾ and his study also reported more number of CIN 
in female patients. Our study had 23 % of females and the occurrence 
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of CIN was 22.5% among them  which is lower than the incidence in 
males that is 77.5% .This is not similar to the Iakovou I et al study. 
Many studies which were done on CIN showed increased 
incidence of CIN to be increased with increasing age. Patients with age 
>75 years are at more risk of developing CIN compared with patients of 
<75 years.Mehran et al study done in 2004 showed the incidence of 
CIN in patients with age >75 years to be of 21.8%⁽⁵²⁾.In our study of 102 
patients, patients with age >75 years is only one patient and another 
patient had the age equal to 75 years. Hence incidence of CIN in 
accordance with the age could not be studied in our study. 
           One of the most important factor contributing to the incidence 
of CIN is osmolality of the contrast media and it is evidenced in many 
studies. Rudnick et al studied the occurrence of CIN in 1196 patients in 
a prospective manner witnessed  no difference in the incidence of CIN 
between patients who had low osmolar contrast media versus patients 
who had high osmolar contrast media ,who had coronary angiogram. 
This is the incidence in patients who were non –diabetic.But in patients 
who were diabetic with already existing renal insuffiency in the form of 
elevated serum creatinine the use of low osmolar contrast media is 
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associated with decreased incidence of CIN when compared with the 
usage of high osmolar contrast media⁽¹⁵⁾. Another study by Barrett and 
Carlisle associated the occurrence of renal injury with the use of 
contrast agents in 14 trials and found that the incidence of CIN was 
more in patients who had contrast using procedures with high osmolar 
agent than in the patients who had the procedures with low osmolar 
contrast agent, especially in patients with already existing renal 
dysfunction⁽³⁹⁾. Another study by Aspelin et al in 2003 showed the 
above result⁽⁴³⁾. Our study used only low osmolar contrast agent and 
hence the effect of osmolality of the contrast media on the incidence 
of CIN could not be studied. 
           Another factor which is considered to be one of the important 
contributing factor in the occurrence of CIN is the volume of contrast 
media used⁽⁵’⁹⁵⁾. Rihal et al study in more than 7000 patients showed 
each 100 ml contrast media to increase the ratio of CIN by 1.12.⁽⁵⁾ 
              Our study limited the use of contrast media to a lesser volume 
of 30-50 ml only. Hence the relation to the occurrence of CIN  with the 
effect of increased volume of contrast media could not be studied. 
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           Underlying renal dysfunction is one of the important contributing 
factor for the occurrence of CIN. Many studies like Rihal et al study⁽⁵⁾ 
and Murphy SW et al study⁽⁹⁶⁾ have clearly showed the relation. Since 
in our study we had excluded the patients with already existing renal 
dysfunction, this factor could not be studied. 
          Diabetes was an important contributing factor in the incidence of 
CIN. Many studies have showed that. Mehran et al study showed that 
the incidence was around 12.5 %⁽⁵²⁾. Gussenhoven MJ et al ⁽⁹⁷⁾ study 
and Gruberg et al⁽⁶⁾ study showed an incidence of 5%-30% among 
diabetic patients. Our study showed that the diabetes is an important 
contributing factor in the ocurrnce of CIN. The incidence of CIN in 
diabetic patients was found to be 34.3 % and it is statiscally significant 
with a p value of 0.049.  
     Hypertension is also an important contributing factor in the 
ocurrance of CIN. Iakovou I et al study ⁽⁸⁾, Mehran et al⁽⁵²⁾ study  are 
some of the studies which showed the contribution of hypertension in 
the occurrence of CIN. However the study by Gruberg L et al ⁽⁶⁾ did not 
show the contribution by hypertension to the occurrence of CIN. Our 
study did not show a statiscally significant relationship between 
hypertension and contrast induced nephropathy. 
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          Use of nephrotoxic antibiotics and analgesics- NSAIDS and the 
incidence of CIN were studied by Louis BM et al ⁽⁵⁷⁾ and Kolonko et al 
⁽⁵⁹⁾. They were found to be associated with the incidence of CIN. Our 
study did not show a statiscally significant relationship between the 
use of nephrotoxic antibiotics or NSAIDS. 
          Umruddin Z study(100) showed the incidence of CIN is increased in 
patients using ACE inhibitors or Angiotensin receptor blockers with the 
incidence of 4.55%.In our study ,there is no significant association 
made out. 
Smokers in our study were 38%. The incidence of CIN in smokers 
is 26.3% and it is not stastiscally significant in our study.Smoking 
history has been included in many studies as one of the patient related 
risk factor and its contribution in the incidence of CIN has been shown. 
Studies stating hydration versus no hydration not done 
previously because of lack of a placebo substitute for an intravenous 
hydration. In our study the number of patients who were dehydrated 
at the time of study were 11%. The contribution of these patients to 
the development of CIN was 27.3% with a p value of 0.708 which is 
statiscally insignificant. We did not follow any hydration protocols. 
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Dehydration and the presence of congestive cardiac failure are 
predisposing factors causing decreased perfusion to kidneys ,and thus 
increasing the ischaemic injury with the contrast media 
use.Dehydration status is particularly important in patients with 
multiple myeloma , where the occurrence of CIN is more with patients 
in dehydration. 
In a study by Murakami R et al ,where the effect of anemia in 
the occurrence of CIN in patients with already existing renal 
dysfunction, found that low haemoglobin level remained an 
independent predictor of CIN, with the incidence rate of 7.8% CIN in 
anemic patients⁽⁹⁸⁾. In Li WH et al study, where 1,026 patients 
undergoing PCI were studied, 3.1% developed CIN after the procedure. 
Among them 6.3% of CIN patients had anemia and the incidence in non 
anemic patients was 2.2% with the p value of <0.01⁽⁹⁹⁾. 
In our study, the percentage of patients according to WHO 
criteria is 84.3%.The contribution of anemia as a risk factor for CIN is 
found to be 28.4% with a p value of 0.112 which is statiscally not 
significant. 
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RESULTS 
 
With the variables-Age, Gendor, Smoking, DM, HT, ACE I and 
diuretics usage, NSAIDS and Nephrotoxic antibiotics usage ,as the risk 
factors for the development of contrast induced nephropathy,the  
significant contributing factor in our study is diabetic mellitus with 
totally 35 patients out of 102 ,in whom the incidence of CIN is 12 with 
the percentage of 34.3%. 
          Our study included only a small number of patients (n=102).When 
the number of patients are high in number, the yield of the result could 
be better. Also a long term follow up of the patients is needed. 
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CONCLUSIONS 
 From the 102 patients who underwent contrast using procedure-
coronary angiogram over a period of three months, we concluded the 
following, 
1. The incidence of CIN is 22.5%out of the 102 patients studied. 
2. The contributing risk factors to CIN studied were age and gendor 
of the patients, HT, DM, use of nephrotoxic drugs namely ACE 
inhibitors, NSAIDS, diuretics, nephrotoxic antibiotics. 
3. The significant contributing factor that contributed to CIN in our 
study is Diabetus mellitus with a p value of 0.049. 
4. The mean  s.creatinine value in CIN patients in our study is 1.77 
 
 N Minimum Maximum Mean Std. Deviation 
Age 102 18 78 52.53 10.174 
Hb 102 9.0 16.0 11.729 1.0652 
vol CM 102 30.0 50.0 42.696 6.8097 
Creat –
Baseline 102 .1 1.2 .789 .1711 
Creat- post 
angio 102 .6 2.4 .881 .2864 
CIN 102 1.0 2.4 1.775 .4200 
Valid N 
(listwise) 102     
.  
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SUMMARY 
         CIN is actually an iatrogenic form of disease. It is found in patients 
who are at risk and has an adverse outcome. There are many studies 
about CIN, but the definition and the inclusion criteria are not definite 
or conclusive. Careful selection of the patient ,decreasing the amount 
of contrast used by careful titering , proper periprocedural hydration 
have been found to decrease the incidence of CIN. ⁽⁽⁰⁰⁰⁰⁾⁾Also  low or 
iso-osmolar contrast agents have lower renal injury when compared 
with high osmolar agents, hence they are found to have better safety 
profile.Drugs or medicines which are nephrotoxic should not be used 
for atleast 48 hours before the procedure. Hypotension should be 
corrected.Prophylactic hemofiltration should be done in very high risk 
individuals six hours before a complicated procedure, but guidelines or 
studies regarding it is available less. In patients who have already 
existing renal disease, hydration should be given 12 hours before the 
contrast using procedure and should be given for atleast 24 hours post 
procedure. Shorter interval between contrast procedures should 
always be avoided. Studies regarding N-acetyl cysteine is not complete, 
but the drug is cheaper, easy to administer and has decreased side 
effects. Its effects are better with higher doses. 
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In everyday clinical practice, the key role in patient protection 
from contrast-induced nephropathy is the proper monitoring of renal 
function, identification of patients with risk factors, and introduction of 
effective preventive measures. One of the most important components 
of comprehensive prophylaxis is close cooperation between the 
radiologist and the clinician referring the patient for contrast-enhanced 
procedures. The result of such cooperation is unquestionably a 
responsible referral of the patients for examinations and proper 
preparation of these patients, for example by development of a proper 
medical history questionnaire filled out before the examination, with 
involvement of the clinician, and allowing the radiologist to make 
conscious decisions and to plan the entire process before and after the 
examination. 
 
 
 
 
 
 
90 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
91 
SCOPE FOR FUTURE STUDIES 
 
      The study done dealt with only some of the contributing 
factors for the occurrence of CIN. Furthur studies in the future should 
be concentrated on the prevention of CIN and prophylactic measures 
taken for the prevention of CIN.We have not included patients who are 
undergoing emergency angiographic procedure .There the risk factors 
are likely to be more and unique. Also such a setting will help in 
delineating the risk factors better.The possibility of further 
deterioration in renal function and permanent damage to renal 
function can be made out only if we do long term follow up of the 
patients who are developing CIN. 
.  
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CONSENT  FORM 
1).  I agree to participate in the study entitled  ‘THE INCIDENCE OF 
CONTRAST NEPHROPATHY IN PATIENTS UNDERGOING 
CONTRAST IMAGING STUDY-CORONARY ARTERY ANGIOGRAM 
WITH NORMAL RENAL FUNCTION 
2). I confirm that I have been told about this study in my mother 
tongue and have had the opportunity to ask questions  
3).  I understand that my participation is voluntary and I may refuse 
to participate at any time without giving any reasons and 
without affecting my benefits. 
4).  I agree not to restrict the use of any data or results that arise 
from this study. 
 
Name of the participant : 
Sign / Thumb print : 
Sign of the Investigator 
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PROFORMA 
Name : 
Age / Sex :       Marital Status : 
Educational Status :     Occupation : 
Address : 
Contact No : 
 
Clinical features:- 
Facial puffiness 
Generalised Edema 
Urine frequency 
Dysuria 
Burning Micturation 
Altered sensorium 
Loss of consciousness 
Pleural Effusion 
Ascitis 
Fever 
 
Past History:- 
SLE………………………………………………(duration…………….;treatment………………) 
Diabetes Mellitus……………………….( duration……………treatment………………..) 
Hypertension…………………………….( duration ……….;treatment………………….) 
IHD……………………………………........(duration………………..;treatment……………) 
Stroke………………………………………(duration………………..;treatment……………) 
Renal disease 
Other Autoimmune Disease 
Liver disease 
Thyroid dysfunction 
Other Significant Past History : 
 
 Personal History: 
Diet  - vegetarian / non-vegetarian /mixed / fruits / fast food 
Bowel  - normal / constipation / loose stools 
Bladder - normal / polyuria / oliguria 
Smoking  
Alcohol:  
Tobacco   
109 
Treatment History Any H/o NSAID drug  or Nephrotoxic antibiotics intake 
General Physical Examination 
Pallor 
Icterus  
Cyanosis 
Clubbing 
Lymphadenopathy 
Pedal oedema 
 
Vitals: 
Temperature ( in F ) 
Pulse  ( /min) 
BP ( mm of Hg ) 
Pulse pressure ( mm of Hg ) 
Respiratory Rate 
  
Systemic Examination : 
CVS : 
RS: 
PA: 
CNS: 
ECG: 
X ray chest : 
Investigations : 
Hb : 
TC : 
DC: 
ESR 
Platelet : 
Renal Parameters : 
B.Urea, 
S.Creatinine 
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URINE  
Sugar : 
Protein  ( qualitative ) : + / ++ / +++ 
Albumin 
Cells / Casts 
 
Ultrasound Abdomen : 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sl. No.Name Age Gendor Smoker HT DM ACE 1 DIUR NSAID NEP AB DeHy Hb vol CM Creat -B Creat- P CIN
1 Kesaram 55 1 2 2 1 1 2 1 2 2 12 50 0.6 0.7 2
2 Bhasker 62 1 1 1 1 1 2 2 2 2 16 30 0.9 0.8 2
3 Ramaiah 59 1 2 2 2 2 2 1 2 2 14 30 0.9 0.9 2
4 Ilango 55 1 1 2 2 2 2 2 2 2 13 50 0.8 0.9 2
5 citibabu 60 1 2 2 2 2 2 2 2 1 12 30 0.8 0.6 2
6 Gnanasekaran 51 1 2 1 1 1 2 2 2 2 11.8 30 1 1.3 1
7 selvi 47 2 2 2 1 2 2 2 2 2 11 50 0.8 0.7 2
8 sathyavathy 48 2 2 2 2 2 2 1 2 2 11.9 30 0.6 0.6 2
9 ramasamy 40 1 1 1 2 2 1 2 2 2 12.5 50 0.6 0.6 2
10 Rajan 38 1 2 2 2 2 2 2 2 1 13 50 0.7 0.6 2
11 malliga 57 2 2 1 2 1 1 1 2 2 10.6 50 0.8 0.7 2
12 Gopikrishna 27 1 2 1 2 2 2 2 2 1 13 50 0.8 0.8 2
13 svasamithran 65 1 2 2 2 1 2 1 2 2 11 30 0.8 1 1
14 Ramachandran 65 1 2 2 2 2 2 2 2 2 12.3 30 0.8 0.8 2
15 Kovilpillai 45 1 1 1 2 1 2 2 2 2 10 50 0.6 0.6 2
16 prabha 50 2 2 2 1 1 2 1 2 2 11 40 0.7 0.8 2
17 Mayarathy 55 2 2 2 1 1 2 1 2 2 11 40 0.7 0.8 2
18 Susairaja 53 1 1 2 2 2 2 2 2 2 12 50 1 0.9 2
19 Malathy 55 2 2 1 1 1 1 1 2 2 10.6 50 1 0.9 2
20 Subbaiah 55 1 1 2 2 2 2 2 2 2 13 50 0.8 0.9 2
21 Manoj Thomas 52 1 2 2 2 2 2 2 2 2 13 50 0.7 0.7 2
22 Suresh 55 1 2 1 2 2 2 2 2 2 11.4 50 1 1.6 1
23 Lakshmi 42 2 2 2 1 2 2 1 2 2 11.6 50 0.8 0.8 2
24 Shanmugam 65 1 2 2 1 2 2 2 2 2 12 50 0.8 0.9 2
25 Gnananmbigai 35 2 2 2 1 1 2 2 2 2 12.5 50 0.5 0.6 2
26 Gajendran 49 1 1 1 2 2 1 2 2 2 13 40 1 1 2
27 Adilamilagai 55 1 1 1 2 2 2 2 1 2 10.2 40 0.5 1.2 1
28 Siva 72 1 2 2 2 2 2 2 2 1 11.7 50 1.1 1.1 2
29 Marimuthu 75 1 1 2 2 2 2 2 2 2 11.9 50 1.1 1.16 2
30 Srinivasa 45 1 2 1 1 1 2 1 2 2 12 50 0.8 1.2 1
31 Mohan 57 1 2 1 1 1 1 2 2 2 13.1 50 1.2 1 2
32 Asirvatham 66 1 2 2 2 2 2 1 2 2 12.8 50 0.8 0.8 2
33 Govindhan 47 1 2 2 2 2 2 2 2 2 11 40 1 1.1 2
34 Soundararaj 55 1 1 2 1 1 2 2 2 2 11.9 50 0.6 0.8 1
35 Mani 40 1 2 2 2 2 2 2 2 2 12 40 0.7 0.8 2
36 Puviyarasan 64 1 1 2 1 1 1 1 2 2 11.6 50 0.5 0.9 1
37 Loganathan 45 1 2 1 2 2 2 2 2 2 12.5 30 0.6 0.7 2
38 Ramachandran 64 1 2 2 2 2 2 1 2 2 11.2 30 0.7 0.6 2
39 Iniyan 46 1 1 2 2 2 2 2 2 2 11.2 50 0.8 1 1
40 Rajan 52 1 2 2 2 2 2 2 2 2 11 50 0.9 2.4 1
41 Bhaskar 64 1 2 1 1 1 1 2 2 2 12 50 0.9 0.8 2
42 Periyasamy 47 1 1 2 2 2 2 2 2 2 14 50 0.5 0.9 1
43 Harikrishna 65 1 2 2 2 2 2 2 2 2 12.8 50 0.8 0.9 2
44 Malar 18 2 2 2 2 2 2 2 2 1 12.5 30 0.6 0.7 2
45 munusamy 45 1 1 2 1 1 1 2 2 2 12.4 50 0.6 0.6 2
46 Anwar basha 55 1 1 1 2 2 2 1 2 2 11.5 30 0.8 1.3 1
47 Vincent 47 1 1 2 2 1 2 2 2 2 11.9 50 0.7 0.8 2
48 thangavelu 49 1 1 1 2 2 2 2 2 2 12.5 40 1 0.8 2
49 Pfizer basha 60 1 1 1 2 2 2 2 2 2 11.5 50 0.8 0.7 2
50 Vijaya 60 2 2 2 1 1 2 1 2 2 10 50 0.6 0.7 2
51 Anandhavelu 35 1 1 2 2 2 2 2 2 2 13 50 0.7 0.6 2
52 Girija 40 2 2 2 1 1 2 2 2 2 12 40 0.8 0.7 2
53 Anand Kumar 40 1 1 2 2 2 2 2 2 2 12.9 50 0.1 0.7 2
54 Shahid 37 1 1 2 1 1 2 2 2 2 11.9 50 0.8 0.8 2
55 Rajamary 64 2 2 1 2 2 2 2 2 2 11.4 50 0.7 0.7 2
56 Kalaiarasan 50 1 2 2 1 2 2 2 2 2 12.8 50 0.8 1 1
57 Guna sekaran 53 1 2 1 1 1 2 2 2 2 11 30 0.8 1.5 1
58 Muhamed 60 1 1 2 1 2 1 1 1 1 11 50 0.7 1.1 1
59 Velu 59 1 2 2 2 2 2 2 2 2 10.9 50 1.1 1.1 2
60 Muthu 70 1 2 2 2 2 2 2 2 1 11.6 50 0.8 1.1 1
61 Veerabathran 45 1 1 1 2 1 1 2 2 2 12 30 0.6 0.7 2
62 Yugamoorthi 42 1 2 2 1 2 2 2 2 2 12.2 40 0.7 1 1
63 murugesan 42 1 2 2 2 2 2 2 2 2 11.9 40 0.8 1 1
64 Manivel 44 1 2 2 2 2 2 2 2 2 12 30 0.9 1 2
65 Gunasekaran 40 1 1 2 1 2 2 2 2 2 12.8 30 0.5 0.8 1
66 Hussain 57 1 2 1 2 2 2 2 1 2 12.9 50 1 0.8 2
67 Bharani 52 2 2 1 1 1 2 2 2 2 9.8 50 0.8 0.9 2
68 Peethambaram 50 1 1 1 2 1 2 2 2 2 12.2 30 0.7 1 1
69 subbaiya 60 1 2 2 2 2 2 2 2 1 13.2 50 0.7 0.7 2
70 annappan 66 1 1 2 1 2 2 2 2 2 11.2 50 0.6 0.7 2
71 Kasi 55 1 2 2 2 2 2 2 2 2 12 50 1 0.9 2
72 Elangoram 45 1 1 2 2 2 2 2 2 2 11.8 50 0.8 0.9 2
73 Mariamma 48 2 2 2 1 1 2 2 2 2 10.1 40 0.7 1.1 1
74 Padmini 50 2 2 2 2 2 2 1 2 2 11.4 50 0.8 0.8 2
75 Velu 45 1 2 2 2 2 2 2 2 2 9.6 50 0.9 0.7 2
76 Selvaraj 55 1 1 2 2 2 2 2 2 2 11.8 40 0.8 1.2 1
77 kanchana 61 2 2 1 1 2 2 2 2 2 10.4 40 0.8 1 1
78 Noorayisha 78 2 2 2 1 1 1 2 2 1 10.3 50 1.1 2.3 1
79 Gunasundari 45 2 2 1 2 1 1 1 2 2 10 50 1.1 0.8 2
80 Ayyayasamy 62 1 1 1 2 1 2 2 2 2 11.8 50 0.7 0.6 2
81 Muthumani 45 1 1 2 1 1 2 2 2 2 12 50 0.9 1 2
82 Umapathy 52 1 1 2 2 2 2 1 2 2 12 50 0.9 0.8 2
83 Ranjan 57 1 1 1 2 2 2 1 2 2 10.6 40 0.8 0.7 2
84 Mohanraj 32 1 1 2 2 2 2 1 2 2 10.4 40 0.7 0.8 2
85 Malliga 52 2 2 1 2 2 2 1 2 2 10.6 50 0.9 0.7 2
86 Krishnan 65 1 1 1 1 1 1 2 2 2 12.7 50 0.7 0.8 2
87 Ganapathy 65 1 2 1 1 1 2 1 2 2 9 50 1 1.1 2
88 Rambai 52 2 2 1 2 2 2 2 2 2 11.8 40 0.7 0.7 2
89 Adhilakhsmi 52 2 2 1 2 1 2 2 2 2 12.5 50 0.7 0.6 2
90 Srikumar 40 1 2 2 1 2 2 2 2 2 1.4 50 0.8 0.85 2
91 Kenneith 65 1 2 1 2 2 2 2 2 2 11.4 50 1 0.9 2
92 Durai 50 1 1 2 2 2 2 2 2 2 11.2 50 1.1 0.7 2
93 Soundarraj 55 1 2 2 2 2 2 2 2 1 11 50 1 0.7 2
94 Kumar 55 1 1 1 1 1 2 2 2 2 11 50 0.7 0.8 2
95 Fousea 50 2 2 1 2 2 2 1 2 2 10.8 50 0.9 0.7 2
96 Durai 45 1 1 2 2 2 2 2 2 2 11.9 50 0.9 0.8 2
97 Govindan 57 1 2 2 2 2 2 2 2 2 12.9 50 0.7 0.8 2
98 Peerson 53 1 2 2 2 2 2 1 1 2 11 40 0.6 0.6 2
99 Amritha 65 2 2 2 1 2 2 1 2 2 11.6 50 0.9 0.8 2
100 Harikrishnan 65 1 2 2 2 2 2 1 2 1 10 50 0.8 0.8 2
101 velmurugan 54 1 1 2 2 2 2 2 2 2 11 50 0.6 0.7 2
102 palanisamy 49 1 2 2 2 2 2 2 2 2 12.3 50 0.8 0.9 2
1 - Yes NSAID - Non Steroidal Anti Inflammatory Drugs Creat- B  - Serum Creatinine Before the procedure
2 - No NEP  AB - Nephrotoxic Antibiotics Creat- p  - Serum Creatinine post procedure
Sl. No.Name Age Gendor Smoker HT DM ACE 1 DIUR NSAID NEP AB DeHy Hb vol CM Creat -B Creat- P CIN
DM - Diabites Mellitus ACE I - Angiotensin Converting Enzynyme InhibitorsHB - Hemoglobin
HT - Hypertension DeHy - Dehydration CIN - Contrast Induced Nephropathy
